Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia

Neurobiology of Disease

Volumn 48, Issue 1, 2012, Pages 66-78

  Song, Chang Hyun ^a   Fan, Xueliang ^a   Exeter, Cicely J ^a   Hess, Ellen J ^a   Jinnah, H A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Anatomy; Behavior; Biochemistry; Microdialysis; Mouse mutant; Neuropharmacology

Indexed keywords

AMPHETAMINE; HALOPERIDOL; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; CAUDOPUTAMEN; CELL STIMULATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG RESPONSE; DYSTONIA; MESENCEPHALON; METABOLITE; MICRODIALYSIS; MOTOR ACTIVITY; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; DOPAMINE; DYSTONIA; FEMALE; GAIT; MALE; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MOTOR ACTIVITY; NEURONS; ROTAROD PERFORMANCE TEST;

EID: 84863769133     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.05.009     Document Type: Article

References (58)

1. Asanuma K., et al. The metabolic pathology of dopa-resonsive dystonia. Ann. Neurol. 2005, 57:596-600.
2. Augood S.J., et al. Expression of the early-onset tosion dystonia gene (DYT1) in human brain. Ann. Neurol. 1998, 43:669-673.
3. Augood S.J., et al. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Ann. Neurol. 1999, 46:761-769.
4. Augood S.J., et al. Dopamine transmission in DYT1 dystonia. Adv. Neurol. 2004, 94:53-60.
5. Balcioglu A., et al. Dopamine release is impaired in a mouse model of DYT1 dystonia. J. Neurochem. 2007, 102:783-788.
6. Bruno J.P., et al. Age-dependent neurobehavioral plasticity following forebrain dopamine depletions. Dev. Neurosci. 1998, 20:164-179.
7. Carbon M., Eidelberg D. Abnormal structure-function relationships in hereditary dystonia. Neuroscience 2009, 164:220-229.
8. Cardoso F. Drug-induced dystonia. Handbook of dystonia 2008, 267-276. Informa Healthcare, Inc., New York. M.A. Stacey (Ed.).
9. Dang M.T., et al. Generation and characterization of Dyt1 deltaGAG knock-in mouse as a model for early-onset dystonia. Exp. Neurol. 2005, 196:452-463.
10. Dang M.T., et al. Motor deficits and hyperactivity in Dyt1 knockdown mice. Neurosci. Res. 2006, 56:470-474.
11. Dang M.T., et al. An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 DeltaGAG knock-in mice. Behav. Brain Res. 2012, 226:465-472.
12. Egami K., et al. Basal ganglia dopamine loss due to defect in purine recycling. Neurobiol. Dis. 2007, 26:396-407.
13. Fahn S. Concept and classification of dystonia. Adv. Neurol. 1988, 50. (8-Jan).
14. Fan X., Hess E.J. D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD. Neurobiol. Dis. 2007, 26:201-211.
15. Furukawa Y., et al. Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology 2000, 54:1193-1195.
16. Gonzalez-Alegre P., Paulson H.L. Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J. Neurosci. 2004, 17:2593-2601.
17. Gonzalez-Alegre P., et al. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J. Neurosci. 2005, 25:10502-10509.
18. Goodchild R.E., et al. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005, 48:923-932.
19. Granata A., et al. TorsinA and dystonia: from nuclear envelope to synapse. J. Neurochem. 2009, 109:1596-1609.
20. Grundmann M., et al. Overexpression of human wildtype torsinA and human deltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiol. Dis. 2007, 27:190-206.
21. Hampton T.G., et al. Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol. Behav. 2004, 82:381-389.
22. Hewett J., et al. Function of dopamine transporter is compromised in DYT1 transgenic animal model in vivo. J. Neurochem. 2010, 113:228-235.
23. Jinnah H.A., et al. Amphetamine-induced behavioral phenotype in a hypoxanthine-guanine phosphoribosyltransferase-deficient mouse model of Lesch-Nyhan syndrome. Behav. Neurosci. 1991, 105:1004-1012.
24. Jinnah H.A., et al. Functional analysis of brain dopamine systems in a genetic mouse model of Lesch-Nyhan syndrome. J. Pharmacol. Exp. Ther. 1992, 263:596-607.
25. Jinnah H.A., et al. Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J. Neurosci. 1994, 14:1164-1175.
26. Jinnah H.A., et al. Rodent models for dystonia research: characteristics, evaluation, and utility. Mov. Disord. 2005, 20:283-292.
27. Jones B.J., Roberts D.J. The quantitative measurement of moto inco-ordination in naive mice using an accelerating rotarod. J. Pharm. Pharmacol. 1968, 20:302-304.
28. Joyce J.N., et al. Functional and molecular differentiation of the dopamine system induced by neonatal denervation. Neurosci. Biobehav. Rev. 1996, 20:453-486.
29. Kale A., et al. Ethanol's effects on gait dynamics in mice investigated by ventral plane videography. Alcohol. Clin. Exp. Res. 2004, 28:1839-1848.
30. Konakova M., Pulst S.M. Immunocytochemical characterization of torsin proteins in mouse brain. Brain Res. 2001, 922:1-8.
31. Konakova M., et al. Cellular distribution of torsin A and torsin B in normal human brain. Arch. Neurol. 2001, 58:921-927.
32. Lange N., et al. Behavioural and pharmacological examinations in a transgenic mouse model of early-onset torsion dystonia. Pharmacol. Biochem. Behav. 2011, 97:647-655.
33. Martella G., et al. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 2009, 132:2336-2349.
34. Neychev V.K., et al. The functional neuroanatomy of dystonia. Neurobiol. Dis. 2011, 42:185-201.
35. Neychev V., et al. The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain 2008, 131:2499-2509.
36. Page M.E., et al. Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol. Dis. 2010, 39:318-326.
37. Perlmutter J.S., Mink J.W. Dysfunction of dopaminergic pathways in dystonia. Adv. Neurol. 2004, 94:163-170.
38. Pisani A., et al. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. Neurobiol. Dis. 2006, 24:318-325.
39. Rostasy K., et al. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol. Dis. 2003, 12:11-24.
40. Segawa M., et al. Dopa-responsive dystonia. Handbook of dystonia 2008, 219-244. Informa Healthcare, Inc., New York. M.A. Stacey (Ed.).
41. Sharma N., et al. Impaired motor learning in mice expressing torsinA with the dyt1 dystonia mutation. J. Neurosci. 2005, 25:5351-5355.
42. Shashidharan P., et al. Immunohistochemical localization and distribution of torsinA in normal human and rat brain. Brain Res. 2000, 853:197-206.
43. Shashidharan P., et al. Transgenic mouse model of early-onset dyt1 dystonia. Hum. Mol. Genet. 2005, 14:125-133.
44. Tanabe L.M., et al. Primary dystonia: molecules and mechanisms. Nat. Rev. Neurol. 2009, 5:598-609.
45. Tarsy D., Simon D.K. Dystonia. N. Engl. J. Med. 2006, 355:818-829.
46. Tolosa E., Compta Y. Dystonia in Parkinson's disease. J. Neurol. 2006, 253(Suppl. 7):7-13.
47. Ulug A.M., et al. Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:6638-6643.
48. Visser J.E., et al. Oxidative stress and dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. Dev. Brain Res. 2002, 133:127-139.
49. Wichmann T. Commentary: dopaminergic dysfunction in DYT1 dystonia. Exp. Neurol. 2008, 212:242-246.
50. Wickremaratchi M.M., et al. The motor phenotype of Parkinson's disease in relation to age at onset. Mov. Disord. 2011, 26:457-463.
51. Xiao J., et al. Developmental expression of rat torsinA transcript and protein. Brain Res. Dev. Brain Res. 2004, 152:47-60.
52. Yokoi F., et al. Motor deficits and hyperactivity in cerebral cortex-specific Dyt1 conditional knockout mice. J. Biochem. 2008, 143:39-47.
53. Yokoi F., et al. Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout mice. PLoS One 2011, 6:e24539.
54. Yokoi F., et al. Improved motor performance in Dyt1 DeltaGAG heterozygous knock-in mice by cerebellar Purkinje-cell specific Dyt1 conditional knocking-out. Behav. Brain Res. 2012, 230:389-398.
55. Zaborszky L., Vadasz C. The midbrain dopaminergic system: anatomy and genetic variation in dopamine neuron number of inbred mouse strains. Behav. Genet. 2001, 31:47-59.
56. Zhang L., et al. Altered dendritic morphology of Purkinje cells in Dyt1 DeltaGAG knock-in and purkinje cell-specific Dyt1 conditional knockout mice. PLoS One 2011, 6:e18357.
57. Zhao Y., et al. Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. Exp. Neurol. 2008, 210:719-730.
58. Zhao Y., et al. The DYT1 carrier state increases energy demand in the olivocerebellar network. Neuroscience 2011, 177:183-194.